Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis

Fig. 2

a Kaplan–Meier curve for major adverse cardiac events (MACE). Kaplan–Meier curve for major adverse cardiac events (MACE). In left part MACE cumulative survival curve at 360 days follow up comparing diabetic (green color) vs. non diabetic patients (blue color). In right part MACE cumulative survival curve at 360 days follow up comparing diabetic incretin users (green color) vs. diabetic never-incretin-users patients (blue color). There is a statistical significant higher number of events comparing diabetic vs.non diabetic patients, and incretin-users vs. never-incretin-users (p value < 0.05). b Major adverse cardiac events (MACE) outcome at 1-year follow-up stratified by GLP-1 terziles. After breakfast, blood samples for the measurement of GLP-1 were obtained every 30 min over a 2-h period. The mean of the four GLP-1 evaluations was defined as the postprandial GLP-1 value. Diabetic patients are divided by GLP-1 values in three subgroup: I terzile with GLP-1 values < 20.3 ng/ml; II terzile with GLP-1 values between 20.4 and 23.6 ng/ml; III terzile with GLP-1 values > 23.6 ng/ml. Major number of MACE are associated to I GLP-1 terzile. I GLP-1 terzile is statistical significant higher vs. II and III GLP-1 terzile (respectively marked with symbol *, and ǂ)

Back to article page